Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2003 Marzo;47(1) > The Quarterly Journal of Nuclear Medicine 2003 Marzo;47(1):63-74

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  THERAPY RESPONSE IN NUCLEAR MEDICINE
Guest Editor: Bombardieri E.


The Quarterly Journal of Nuclear Medicine 2003 Marzo;47(1):63-74

lingua: Inglese

Thallium-201 imaging in the assessment of tumor response to anti-tumor treatments

Berk F., Demir H., Aktolun C

Department of Nuclear Medicine, Kocaeli University, School of Medicine, Kocaeli, Turkey


FULL TEXT  


The advan­tag­es and lim­i­ta­tions of 201Tl imag­ing in assess­ing the ­tumor ­response to ­anti-can­cer ther­a­py are dis­cussed in ­this ­review. 201Tl has dis­tinc­tive advan­tag­es but ­more ­recent ­agents ­such as 99mTc ­MIBI and posi­tron emit­ters ­have ­some clin­i­cal super­ior­ities ­over 201Tl in ­this ­usage.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail